ADDISON, Texas, Sept. 20, 2012 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), announced today the receipt of the first European order for the launch of Altrazeal® in Austria.
It is anticipated that Altrazeal® will be launched in Austria in October. Over the past 12 months Altrazeal® has been extensively clinically evaluated at the major wound care centers in Vienna by key opinion leaders. These evaluations have demonstrated the clinical benefits of Altrazeal® in chronic wounds and very importantly the potential to generate significant cost savings for the health care system.
Commenting on the launch of Altrazeal® in Austria, Helmut Kerschbaumer, Chairman of Melmed Holdings AG, stated, "We have conducted extensive pre-marketing activities to generate the necessary key opinion leader support not only in Austria but throughout Europe. The clinical and economic advantages that have been demonstrated are significant benefits that make Altrazeal® a unique product in the wound care market. Also, its ability to inhibit bacterial growth over an extended period when used with different antiseptics is considered a major marketing opportunity. The properties of Altrazeal® including extended wear time, reduced wound care provider treatment time and clinical outcomes make it an ideal product for the European market."
In addition to the activities in Austria there are ongoing programs throughout Europe designed to prepare for the launch of Altrazeal® in additional markets in early 2013. An advisory group with key opinion leaders from all major European countries has been assembled to assist and direct activities to position Altrazeal® for market success. Clinical programs are being developed to clearly demonstrate the economic advantages generated by the use of Altrazeal®
Kerry Gray, President and CEO of ULURU Inc., added, "We are very pleased not only with the progress in Europe but also with the outstanding group of opinion leaders that have been assembled to support the commercialization of Altrazeal® throughout the region. The necessary pre-marketing activities to ensure a successful launch are being conducted which gives us great confidence that Altrazeal® will be a significant competitor in the advanced wound care market."
Altrazeal® is an advanced scientifically engineered material that is unique among all other wound dressings in terms of properties and performance. It incorporates the features and benefits of the desired "ideal" wound dressing. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers, pressure ulcer, and geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to our belief that Altrazeal® will be a major competitor in the wound care market, anticipated product launches in Austria, the cost effectiveness and cost savings of Altrazeal® in healing chronic wounds, Altrazeal's clinical and economic advantages, and Altrazeal's ability to penetrate the European wound care market, and to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us with the Securities and Exchange Commission.
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
|SOURCE ULURU Inc.|
Copyright©2012 PR Newswire.
All rights reserved